MAIA Biotechnology, Inc.

Ateganosine utilizes a dual mechanism of action with direct telomere-targeting and immune system activation. While we advance our lead candidate in NSCLC, R&D continues on our 2nd-generation pipeline for multiple tumor types. bit.ly/4bgzrR1 $MAIA

Ateganosine continues to deliver unprecedented efficacy in third-line NSCLC. Interim Phase 2 data show a median overall survival of 17.8 months - 3x the current chemotherapy standard. Learn more: bit.ly/4bgzrR1 $MAIA

Statistical assessments for MAIA’s Phase 3 THIO-104 trial point to a 99% probability of success at final analysis. Supported by FDA Fast Track designation and an NIH grant, we are accelerating our path toward potential commercial approval. bit.ly/4bgzrR1 $MAIA

With FDA Fast Track designation and an ongoing Phase 3 full approval study, ateganosine is being developed as a potential treatment for the 3L NSCLC population and the foundation of a new treatment category. Read more: bit.ly/4kVTXuD $MAIA

Today, MAIA CEO Vlad Vitoc, M.D., shared a 2026 Letter to Shareholders outlining Phase 3 momentum behind ateganosine in development as a treatment for NSCLC and its potential in the $50 billion immunotherapy market. Read more: bit.ly/4kVTXuD $MAIA

On #WorldCancerDay, we recognize the patients and families affected by cancer. MAIA’s ateganosine is an investigational therapy in late-stage trials for NSCLC. Learn more: maiabiotech.com/pipeline/thio/ $MAIA

FDA Fast Track designation remains a key part of MAIA’s ateganosine strategy, enabling continued dialogue as late-stage clinical trials progress. Details: bit.ly/4r1SDYG $MAIA

Late-stage clinical development continues at MAIA. Ateganosine is advancing through a pivotal Phase 3 trial alongside an expanded Phase 2 study in NSCLC, with multiple data readouts expected to inform next regulatory steps. Learn more: bit.ly/4r1SDYG $MAIA

Ateganosine remains the only direct telomere-targeting therapy in clinical development for NSCLC. MAIA continues to leverage its differentiated approach while preparing second-generation molecules for clinical evaluation. Learn more: bit.ly/4r1SDYG $MAIA

MAIA highlights progress and priorities for 2026, including FDA Fast Track designation for ateganosine in NSCLC and concurrent Phase 2/3 trials advancing toward key clinical milestones. Read more here: bit.ly/4r1SDYG $MAIA

Only telomere-targeting agent in clinical development: ateganosine begins pivotal Phase 3 trial for advanced NSCLC, with statistical models showing high probability of technical success for regulatory approval. bit.ly/48J7UpW $MAIA

NSCLC market poised to nearly double to $68.8B by 2033. MAIA’s ateganosine addresses the largest unmet need: patients without actionable mutations or CPI response. Read the release for more information: bit.ly/4q6zNzs

First patient dosed in THIO-104, MAIA’s pivotal Phase 3 trial for ateganosine in third-line NSCLC. FDA Fast Track designated; global enrollment active. Get the details: bit.ly/4prIy77 $MAIA

MAIA’s leadership continues to demonstrate a unified stance. Recent insider buying in 2025 demonstrates confidence in the company’s strategy, ateganosine’s growing body of clinical evidence, and the opportunity ahead. ICYMI: bit.ly/4a5p1od $MAIA

The $34.1B NSCLC market, projected to double, is ready for disruption. $MAIA is positioned with ateganosine to capture value in the CPI-refractory population. Commercial opportunity spans Glioblastoma, HCC, and SCLC, backed by FDA ODDs. View our strategy: bit.ly/4q6zNzs

MAIA's ateganosine is a first-in-class telomere-targeting agent that exploits a universal cancer feature. Its dual mechanism triggers cancer cell death and activates immune response. Phase 3 THIO-104 has begun under FDA Fast Track. Full release: bit.ly/48J7UpW $MAIA

In case you missed it: MAIA's Phase 3 program reached a key milestone with the first patient dosed in our pivotal trial. Progress towards FDA approval underway. Details: bit.ly/4prIy77 $MAIA

MAIA’s emerging clinical results continue to surpass expectations. Ateganosine advances toward Phase 3 as the only direct telomere-targeting anticancer agent currently in clinical development anywhere. Full release: bit.ly/48J7UpW $MAIA

MAIA achieves a key milestone, the first patient dosed in the THIO-104 phase 3 pivotal trial. This trial evaluates ateganosine sequenced with a CPI as a third-line treatment for advanced NSCLC patients who are CPI/chemo-resistant. Read the release: bit.ly/4prIy77 $MAIA

MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential. Read the release: bit.ly/4a5p1od $MAIA